253 related articles for article (PubMed ID: 22740985)
41. Nitrogen and Sulfur Co-doped Carbon-Dot-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Imaging for Profiling Bisphenol S Distribution in Mouse Tissues.
Lin Z; Wu J; Dong Y; Xie P; Zhang Y; Cai Z
Anal Chem; 2018 Sep; 90(18):10872-10880. PubMed ID: 30139256
[TBL] [Abstract][Full Text] [Related]
42. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
Hortin GL
Clin Chem; 2006 Jul; 52(7):1223-37. PubMed ID: 16644871
[TBL] [Abstract][Full Text] [Related]
43. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.
Issaq HJ; Veenstra TD; Conrads TP; Felschow D
Biochem Biophys Res Commun; 2002 Apr; 292(3):587-92. PubMed ID: 11922607
[TBL] [Abstract][Full Text] [Related]
44. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.
Silsirivanit A; Sawanyawisuth K; Riggins GJ; Wongkham C
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):388-96. PubMed ID: 24616382
[TBL] [Abstract][Full Text] [Related]
45. New approaches to proteomic analysis of breast cancer.
Wulfkuhle JD; McLean KC; Paweletz CP; Sgroi DC; Trock BJ; Steeg PS; Petricoin EF
Proteomics; 2001 Oct; 1(10):1205-15. PubMed ID: 11721633
[TBL] [Abstract][Full Text] [Related]
46. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
47. Matrix-assisted laser desorption/ionization time of flight mass spectrometry for comprehensive indexing of East African ixodid tick species.
Rothen J; Githaka N; Kanduma EG; Olds C; Pflüger V; Mwaura S; Bishop RP; Daubenberger C
Parasit Vectors; 2016 Mar; 9():151. PubMed ID: 26979606
[TBL] [Abstract][Full Text] [Related]
48. The application of SELDI-TOF-MS in clinical diagnosis of cancers.
Liu C
J Biomed Biotechnol; 2011; 2011():245821. PubMed ID: 21687541
[TBL] [Abstract][Full Text] [Related]
49. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer.
Fels LM; Buschmann T; Meuer J; Reymond MA; Lamer S; Röcken C; Ebert MP
Dig Dis; 2003; 21(4):292-8. PubMed ID: 14752218
[TBL] [Abstract][Full Text] [Related]
50. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.
Cheng L; Zhou L; Tao L; Zhang M; Cui J; Li Y
J Cancer Res Clin Oncol; 2008 Jul; 134(7):769-76. PubMed ID: 18202856
[TBL] [Abstract][Full Text] [Related]
51. Identification of potential prognostic markers for knee osteoarthritis by serum proteomic analysis.
Takinami Y; Yoshimatsu S; Uchiumi T; Toyosaki-Maeda T; Morita A; Ishihara T; Yamane S; Fukuda I; Okamoto H; Numata Y; Fukui N
Biomark Insights; 2013; 8():85-95. PubMed ID: 23935359
[TBL] [Abstract][Full Text] [Related]
52. A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis: detection of three biomarkers.
Avasarala JR; Wall MR; Wolfe GM
J Mol Neurosci; 2005; 25(1):119-25. PubMed ID: 15781972
[TBL] [Abstract][Full Text] [Related]
53. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study.
Torres I; Giménez E; Vinuesa V; Pascual T; Moya JM; Alberola J; Martínez-Sapiña A; Navarro D
Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2331-2339. PubMed ID: 30264355
[TBL] [Abstract][Full Text] [Related]
54. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.
Wang Q; Shen J; Li ZF; Jie JZ; Wang WY; Wang J; Zhang ZT; Li ZX; Yan L; Gu J
BMC Cancer; 2009 Aug; 9():287. PubMed ID: 19689818
[TBL] [Abstract][Full Text] [Related]
55. [Clinical proteomics: towards early detection of cancers].
Solassol J; Boulle N; Maudelonde T; Mangé A
Med Sci (Paris); 2005; 21(8-9):722-9. PubMed ID: 16115457
[TBL] [Abstract][Full Text] [Related]
56. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer.
Wulfkuhle JD; Paweletz CP; Steeg PS; Petricoin EF; Liotta L
Adv Exp Med Biol; 2003; 532():59-68. PubMed ID: 12908550
[TBL] [Abstract][Full Text] [Related]
57. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass-Spectrometry (MALDI-TOF MS) Based Microbial Identifications: Challenges and Scopes for Microbial Ecologists.
Rahi P; Prakash O; Shouche YS
Front Microbiol; 2016; 7():1359. PubMed ID: 27625644
[TBL] [Abstract][Full Text] [Related]
58. Matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for the identification of Neisseria gonorrhoeae.
Buchanan R; Ball D; Dolphin H; Dave J
Clin Microbiol Infect; 2016 Sep; 22(9):815.e5-815.e7. PubMed ID: 27371346
[TBL] [Abstract][Full Text] [Related]
59. Proteomic approach to breast cancer.
Laronga C; Drake RR
Cancer Control; 2007 Oct; 14(4):360-8. PubMed ID: 17914336
[TBL] [Abstract][Full Text] [Related]
60. [Research progress in SELDI-TOF MS and its clinical applications].
Cho WC
Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):871-6. PubMed ID: 17168305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
